Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268474 · ClinicalTrials.gov registry record · NA
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
A NA study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, sponsored by Cutera.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT02268474 is a NA study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea that has completed, run by Cutera. The registered enrollment target is 22 participants, below the 277-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02268474, a NA study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, has completed, sponsored by Cutera.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.
Conditions Studied
Interventions
- DEVICE 532nm KTP Laser vs 595nm Pulse Dye Laser
Study Locations (1)
Florida
- Miami Dermatology & Laser Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268474
The ClinicalTrials.gov registry entry for NCT02268474 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (92% lower). The listed sponsor is Cutera, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Papulopustular Rosacea appearing as the primary indexed condition, and to 1 intervention - of which 532nm KTP Laser vs 595nm Pulse Dye Laser is the first listed.
NCT02268474 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02268474 about?
NCT02268474 is a clinical study titled "Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea". A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.
What is the current status of trial NCT02268474?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2014-09. Estimated completion is 2015-08.
What conditions does trial NCT02268474 study?
This clinical trial studies the following conditions: Papulopustular Rosacea, Erythematotelangiectatic Rosacea.
What interventions are being tested in trial NCT02268474?
The interventions under investigation include: 532nm KTP Laser vs 595nm Pulse Dye Laser (DEVICE).
Who is sponsoring clinical trial NCT02268474?
This trial is sponsored by Cutera, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02268474 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
COMPLETED · Phase 4
-
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
COMPLETED · Phase 3
-
A Twelve Week Safety and Efficacy Study in Rosacea
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.